# Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss

> **NCT03435250** · PHASE1 · TERMINATED · sponsor: **Institut de Recherches Internationales Servier** · enrollment: 123 (actual)

## Conditions studied

- Advanced Solid Tumors
- Lymphoma

## Interventions

- **DRUG:** AG-270
- **DRUG:** AG-270
- **DRUG:** AG-270
- **DRUG:** docetaxel
- **DRUG:** nab-paclitaxel
- **DRUG:** gemcitabine

## Key facts

- **NCT ID:** NCT03435250
- **Lead sponsor:** Institut de Recherches Internationales Servier
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-04
- **Primary completion:** 2023-04-20
- **Final completion:** 2023-04-20
- **Target enrollment:** 123 (ACTUAL)
- **Why stopped:** Strategic reasons
- **Last updated:** 2024-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03435250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03435250, "Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03435250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*